Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
Authors
Keywords
-
Journal
ACS Omega
Volume 6, Issue 25, Pages 16259-16265
Publisher
American Chemical Society (ACS)
Online
2021-06-15
DOI
10.1021/acsomega.1c01755
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lumasiran: First Approval
- (2021) Lesley J. Scott et al. DRUGS
- Inclisiran: First Approval
- (2021) Yvette N. Lamb DRUGS
- Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
- (2020) Daniel P. Judge et al. CARDIOVASCULAR DRUGS AND THERAPY
- Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid (siRNA), Givosiran, in Patients with Acute Hepatic Porphyria
- (2020) Sagar Agarwal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Givosiran: First Approval
- (2020) Lesley J. Scott DRUGS
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
- (2020) Alexandre J. Debacker et al. MOLECULAR THERAPY
- Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
- (2020) Manisha Balwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
- (2020) Christopher R Brown et al. NUCLEIC ACIDS RESEARCH
- Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
- (2019) Eliane Sardh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current and innovative emerging therapies for porphyrias with hepatic involvement
- (2019) Antonio Fontanellas et al. JOURNAL OF HEPATOLOGY
- Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
- (2019) Yanfeng Wang et al. Expert Opinion on Drug Metabolism & Toxicology
- Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
- (2019) Jessica E. Sutherland et al. Nucleic Acid Therapeutics
- Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo
- (2018) Vivek K. Sharma et al. BIOCONJUGATE CHEMISTRY
- The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
- (2018) Maja M. Janas et al. TOXICOLOGIC PATHOLOGY
- Therapeutic Oligonucleotides: State of the Art
- (2018) C.I. Edvard Smith et al. Annual Review of Pharmacology and Toxicology
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
- (2017) Michael Tanowitz et al. NUCLEIC ACIDS RESEARCH
- Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
- (2017) Karsten Schmidt et al. NUCLEIC ACIDS RESEARCH
- Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes
- (2016) Garth A. Kinberger et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
- (2016) Abigail Liebow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys
- (2016) Rosie Z. Yu et al. Nucleic Acid Therapeutics
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
- (2016) Rosie Z Yu et al. Molecular Therapy-Nucleic Acids
- siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes
- (2015) Shigeo Matsuda et al. ACS Chemical Biology
- Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
- (2015) Anisha A. D'Souza et al. JOURNAL OF CONTROLLED RELEASE
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Liver as a target for oligonucleotide therapeutics
- (2013) Alfica Sehgal et al. JOURNAL OF HEPATOLOGY
- The Asialoglycoprotein Receptor Regulates Levels of Plasma Glycoproteins Terminating with Sialic Acid α2,6-Galactose
- (2008) Lindsay M. Steirer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now